537033-52-6

Basic information

• Product Name: 2-(4-broMo-2,6-difluorophenyl)acetonitrile
• Synonyms: 2-(4-broMo-2,6-difluorophenyl)acetonitrile;2,6-Difluoro-4-broMobenzyl Cyanide;4-BroMo-2,6-difluorobenzeneacetonitrile
• CAS NO: 537033-52-6
• Molecular Formula: C₈H₄BrF₂N
• Molecular Weight: 232.0248664
• Mol File: 537033-52-6.mol

Chemical Properties

• Boiling Point: 269.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.654±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(4-broMo-2,6-difluorophenyl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-broMo-2,6-difluorophenyl)acetonitrile(537033-52-6)
• EPA Substance Registry System: 2-(4-broMo-2,6-difluorophenyl)acetonitrile(537033-52-6)

Safety Data

• Hazardous Substances Data: 537033-52-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-bromo-2,6-difluorophenyl)acetonitrile is used as an intermediate compound for the synthesis of azolidinone antibacterials. These antibacterial agents are essential in the development of new drugs to combat bacterial infections, particularly those caused by drug-resistant strains. The unique structure of 2-(4-broMo-2,6-difluorophenyl)acetonitrile allows for its incorporation into the molecular framework of azolidinone derivatives, enhancing their antibacterial properties and effectiveness against a wide range of bacterial pathogens.

Upstream product

• 162744-60-7 5-bromo-2-(bromomethyl)-1,3-difluoro-benzene 
• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 
• 773837-37-9 sodium cyanide 
• 869361-54-6 4-bromo-2,6-difluorobenzyl methanesulfonate 
• 151-50-8 potassium cyanide 

Downstream Products

• 537033-54-8 2-(4-bromo-2,6-difluorophenyl)acetic acid 
• 872089-12-8 2-(4-bromo-2,6-difluorophenyl)acetyl chloride 
• 872089-17-3 [7-(4-bromo-2,6-difluoro-phenyl)-6-chloro-pyrido[2,3-b]pyrazin-8-yl]-sec-butyl-amine 
• 872089-15-1 7-(4-bromo-2,6-difluoro-phenyl)-8-hydroxy-5H-pyrido[2,3-b]pyrazin-6-one 
• 872089-13-9 methyl 3-[2-(4-bromo-2,6-difluoro-phenyl)-acetylamino]-pyrazine-2-carboxylate 
• 872089-16-2 7-(4-bromo-2,6-difluoro-phenyl)-6,8-dichloro-pyrido[2,3-b]pyrazine 
• 749929-80-4 2-(4-bromo-2,6-difluoro-phenyl)-2-methyl-propionitrile 
• 749931-06-4 1-(4-bromo-2,6-difluoro-phenyl)-cyclopropanecarbonitrile 
• 1426050-70-5 2-bromo-2-(4-bromo-2,6-difluorophenyl)acetamide 
• 1426050-43-2 2-(4-bromo-2,6-difluorophenyl)acetamide 
• 1426050-47-6 2-(4-bromo-2,6-difluorophenyl)-2-(4-cyclopropyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl acetate 
• 1426050-46-5 2-bromo-2-(4-bromo-2,6-difluorophenyl)ethyl acetate 
• 1426050-45-4 4-bromo-2,6-difluorophenethyl acetate 
• 1426050-44-3 2-(4-bromo-2,6-difluoro-phenyl)ethanol 

Relevant articles and documents

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.

FUNGICIDES BASED ON NITROGEN-CONTAINING HETEROCYCLES

The compound of the general formula (I), wherein W, X, Y, Z, R, R1 and R2 are defined as set forth in the specification, useful as fungicide.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).